P0069 ViraQ HBV Trend 25 P0069
|
|
- Stephen Wilcox
- 5 years ago
- Views:
Transcription
1 P0069 ViraQ HBV Trend 25 P0069 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance
2 Table of contents Intended Use... 3 Key to Symbols Used... 3 Principle of method... 3 Traceability of HBV-DNA concentration in IU/mL and copies/ml... 4 Kit Contents... 5 Storage Instructions... 5 Warning and precautions... 5 Test Procedure... 6 Expected assay response values... 6 Interpretation of results... 6 Performance characteristics... 6 Limitations... 8 References... 9 P0069 ViraQ HBV Trend 25 2
3 Intended Use P0069 ViraQ HBV Trend 25 is intended to be used as external run control for monitoring consistency in analytical sensitivity of multiplex nucleic acid test (NAT) blood screening assays for detection of HBV-DNA as defined in Table 1. P0069 ViraQ HBV Trend 25 is not a replacement for the internal kit controls or calibrators required for the release of test results. The product is intended for performance evaluation only. Table 1. Nucleic acid blood screening kits covered by this run control Manufacturer Equipment Agent Test kits Hologic/Grifols Diagnostic Solutions TIGRIS PANTHER Hepatitis B virus Procleix ULTRIO Plus Procleix ULTRIO Elite Key to Symbols Used Manufacturer Lot number Catalogue number Store below -30 C Biological substance Category B Do not re-use Device for performance evaluation Expiry date Contents Caution Read instructions for use Principle of method P0069 ViraQ HBV Trend 25 enables blood screening laboratories to monitor the analytical sensitivity of transcription mediated amplification (TMA) assays for the qualitative detection of hepatitis B virus (HBV)-DNA in plasma or serum samples. The external run control is designed to mimic naturally occurring plasma specimens with a low concentration of HBV-DNA. The concentration of HBV-DNA in P0069 ViraQ HBV Trend 25 control samples is set at 25 copies (cps)/ml as measured in replicate Siemens bdna 3.0 assays (equivalent to 4.7 International Units (IU)/mL). This level is chosen close to the 95% lower limit of detection (LOD) of the Ultrio Plus and Ultrio Elite 1-4 assays. The external run control generates sample to cut-off (S/CO) ratios in the saturation, dynamic and negative ranges of the Ultrio assay versions. Changes in frequency of non-reactive, dynamic and saturated reactive results on the run control over time may indicate suboptimal performance of the automated NAT screening systems or deterioration of assay reagents. The external run control tubes are barcoded and comparable in size to blood donor collection tubes. The thawed tubes are ready for use and can be placed at random positions in laboratory equipment sample racks. P0069 ViraQ HBV Trend 25 3
4 Traceability of HBV-DNA concentration in IU/mL and copies/ml Traceability and securing continuous and stable performance of P0069 ViraQ HBV Trend 25 is based on four viral standards (figure 1) described below: Historically the EUROHEP genotype A 5 was the first HBV-DNA standard used for standardisation purposes. The 1 st, 2 nd and 3 rd WHO HBV-DNA standards 6,7,8 are 1:500 dilutions of the EUROHEP genotype A standard. The primary standard is the 1 st WHO HBV-DNA international standard (97/746) with an assigned value in IU/ml. The secondary VQC-Sanquin HBV-DNA genotype A standard (S0011) was prepared by mixing plasma units from one donor. A homogeneous pool was aliquoted, snap frozen in liquid nitrogen and stored at -70 C 9. The tertiary inactivated BQC HBV-DNA genotype A standard (S0043) was prepared by heat inactivation of a 1:2500 dilution of the native VQC-Sanquin HBV-DNA genotype A standard (S0011) 9,10,11,12. Subsequently P0069 ViraQ HBV Trend 125 is manufactured by gravimetrically recorded dilution steps from S0043. Figure 1: Traceability chain of P0069 HBV Trend control to the EUROHEP genotype A standard, 1 st WHO IS (97/746), the VQC-Sanquin HBV-DNA genotype A standard and BQC inactivated HBV-DNA genotype A standard. The closed arrows indicate a calibration experiment, while the open arrows depict manufacturing steps. BQC has quantified its viral standards in copies/ml using the branched (b) DNA 3.0 test as the reference assay 12. Expression in nucleic acid copies/ml (which is a SI unit) allows comparison between different viruses, genotypes, limiting dilution analysis for estimating NAT efficiency and relation to 50% minimum infectious dose for understanding residual transfusion transmission risk (the MID50 is estimated at 3.16 (1-10) copy) 13,14,15,16. The HBV DNA concentration in copies/ml (and 95% confidence interval (C.I.)) was originally established in suitable dilutions of the S0011 VQC-Sanquin standard in 28 Siemens bdna P0069 ViraQ HBV Trend 25 4
5 3.0 assays at 2.15 ( ).10 8 copies/ml as was estimated from the results reported in proficiency studies and in house testing at Sanquin. The secondary S0011 VQC Sanquin standard was calibrated against the International Standard in the WHO collaborative study 6 and when analysing the results of bdna 3.0 assay separately 1 IU was found to be equivalent to 5.33 ( ) copies/ml. The S0043 BQC standard has been quantified against the S0011 VQC Sanquin HBV standard in 2 x 6 bdna 3.0 assays on suitable dilutions at a concentration (95%CI) of 7.23( ).10 6 copies/ml. The calibration of the S0043 BQC inactivated standard against the S0011 VQC-Sanquin standard was also compared by Ct analysis (13 x 2 parallel assays) on 2000 copies/ml samples. Samples of the two preparations tested in TaqScreen 2.0 assay showed a potency (95%C.I.) of the latter standard of 1.22 ( ) 17. The production and quality control methods are designed such that the traceability to the primary and secondary standards as described above is guaranteed and that the virus concentration in consecutive batches of P0069 HBV Trend 25 run control (95%CI) is maintained consistently at 25 (18-38) copies/ml or 3.4 ( ) IU/mL. Kit Contents 10 Tubes, each containing 1.5 ml run control without preservatives in polypropylene tubes with screw caps. Storage Instructions Store the run controls at or below -30 C for a maximum of two years (reference actual expiry date). Stability experiments showed less than 10% degradation of HBV-DNA after storing samples in liquid format at 2-8 C and at room temperature for 8 hours. Warning and precautions P0069 ViraQ HBV Trend 25 contains HBV particles that are inactivated by a pasteurization procedure guaranteeing sufficient reduction of infectivity. The plasma matrix is prepared from human plasma tested negative for blood borne virus markers (HBV-DNA, HCV-RNA, HIV-RNA, HBsAg, anti-hbc, anti-hiv, anti-hcv and anti- Treponema pallidum). No test method can offer complete assurance that products derived from human blood cannot transmit (unknown) infectious agents. Observe the universal precautions for prevention of transmission of infectious agents when handling these materials 18,19. Do not pipette by mouth. Use personal protective equipment, including lab coats, gloves and safety glasses. Do not eat, drink or smoke in areas where HBV run controls are handled. Disinfect spills using a 0.5% hypochlorite solution (1:10 v/v household bleach) or equivalent disinfectant. Dispose unused or spilled materials according to the normal practices for biological waste disposal in your institution. If precipitates are visible, mix the run controls for 2 minutes thoroughly. P0069 ViraQ HBV Trend 25 5
6 Test Procedure Thaw the run control quickly in a water bath at 37 C, by gently mixing until frozen contents are just thawed. Remove the run control tube from the water bath immediately. Vortex the run control. Give a short spin in a centrifuge before releasing screw cap from vial. Minimise the time period from thawing until usage of the run control. When not used immediately place in refrigerator. The duration is limited to 8 hours storage until use. The controls should be handled and tested in a manner identical to that of clinical specimens in the assay procedure being evaluated. The external run control tubes are barcoded for automated data-processing. The run controls can be placed at random positions in sample racks of the equipment. After testing discard the remaining run control. Note: To minimize degradation of HBV-DNA in the run control do not leave the run control longer than 8 hours on the NAT equipment before the actual processing of the sample in the assay. Do not refreeze! Expected assay response values Qualitative detection of HBV DNA in Grifols Procleix Ultrio Plus and Elite The expected distribution of assay response values on P0069 ViraQ HBV Trend 25 Control per 1000 test runs in the Ultrio assay versions is presented in Table 2. Table 2. Expected distribution of S/CO response values in Ultrio Plus and Elite assays. Range of assay response values Expected frequency per 1000 runs Test runs Interpretation Saturated: S/CO Positive Dynamic: 1 S/CO<12 57 Positive Non-reactive S/CO < Negative Interpretation of results For daily monitoring, the Westgard 20 rules can be applied on non-reactive results which equals the event being outside the 95% confidence interval. To monitor consistency in analytical sensitivity, the frequencies of non-reactive, dynamic and saturated results obtained should be compared to the expected frequencies (Table 2) and/or peer groups. The chi-square test can be used to identify abberant trends. An aberrant trend is defined by p<0.05 and should be investigated to identify the cause. Performance characteristics Quantitation HBV-DNA in run control by viral load assay. The viral load (and 95% CI) results on P0069 ViraQ HBV Trend 25 in quantitative HBV DNA assay are shown in Table 3. Table 3. Measured viral load in P0069 ViraQ Trend 25 (see also limitations) Unitage Average 95 % confidence interval Copies/mL 1 IU/mL Siemens Versant bdna 3.0 assay, only (Figure 1) P0069 ViraQ HBV Trend 25 6
7 Analytical sensitivity of the Ultrio Plus and Elite assay. The analytical sensitivity of the Ultrio Plus and Elite assay versions has been evaluated in different validation studies 1-4,17,19. Table 4 shows the 95% LOD of the Ultrio Plus and Ultrio Elite on the 1 st and 2 nd WHO (97/746 and 97/750), S0011 HBV genotype A and S0043 HBV genotype A inactivated standard (S0043 is used for manufacturing of the run control). From this table it is concluded that the Ultrio Plus and Ultrio Elite assays have the same analytical sensitivity. Thus, P0069 ViraQ Trend 25 is suitable for both assays. Table 4. Analytical sensitivity of Procleix Ultrio versions on Sanquin and BQC HBV-DNA standards and the 2 nd WHO HBV subtype A standard HBV-DNA standard Assay 50% LOD (CI) 95% LOD (CI) n version copies/ml copies/ml Ref EUROHEP genotype A Ultrio Plus ( ) 26 (19-36) 1 st WHO (97/746) Ultrio Plus ( ) 29 (15-59) 17 2 nd WHO (97/750) Ultrio Plus ( ) 27 (23-32) S0011 Sanquin HBV Ultrio Plus ( ) 44 (31-70) genotype A Ultrio Elite ( ) 35 (22-58) 1 S0043 BQC HBV genotype Ultrio Plus (3.6-12) 48 (27-90) A inactivated Ultrio Elite ( ) 41 (24-90) 17 # IU/mL LOD values converted to copies per ml using factor of 5.33 copies per IU. The HBV DNA concentration in P0069 ViraQ HBV Trend 25 Control is set at approximately the 90% LOD of the Ultrio versions. Commutability of the inactivated standard to the native standard The results on standard dilution series of S0043 BQC HBV genotype A inactivated standard were used to design the P0069 ViraQ Trend HBV 25 control at approximately the 90% LOD (or 0.6 x 95% LOD). The test results of Ultrio Plus, Elite on the inactivated S0043 BQC standard differ from the native S0011 VQC-Sanquin standard. It is assumed this (not significant) difference is caused by lack of commutability of the inactivated BQC standard between testing in the bdna assay (used for calibration) and the target Ultrio Plus and Elite. Distribution characteristics of the S/CO results. Figure 2 shows the S/CO values in 193 Ultrio Elite Assay runs on P0069 ViraQ HBV Trend 25 Control in a histogram which confirm the expected reactivity. Obviously, the S/CO values are not normally distributed. A transformation of S/CO values to obtain normally distributed S/CO values appears not possible. Therefore monitoring S/CO response values in Levey-Jennings charts to identify responses outside confidence limits cannot be applied in a statistically valid manner. Only the proportions of S/CO results in the dynamic and negative range can be used to identify lack of performance. Figure 2. S/CO Distribution on P0069 ViraQ HBV Trend 25 in Ultrio Plus Assay (n=193) P0069 ViraQ HBV Trend 25 7
8 Predicted and observed reactivity rate in Ultrio versions. The observed non-reactivity levels in two different ViraQ HBV DNA run controls of 125 and 25 copies/ml in Ultrio Plus (P0065 and P0069) are decreased when compared to probit analysis data on BQC standard dilution series (P0031) in Ultrio Plus and Elite; combined (Table 5). When compared to the claimed reactivity by the manufacturer the results on the run control confirm consistency in reactivity of Ultrio Plus and Elite, Ultrio batches and run control batches. BQC product HBV-DNA level Copies/mL Table 5. Predicted and observed number of non-reactive response values in Ultrio assays of non-reactive non-reactive results Predicted number Observed number of results per 1000 per 1000 P0031 BQC HBV DNA standard dilution panel 1 x 95% LOD N.A. P0065 ViraQ Check x 95% LOD (0/339) P0069 ViraQ Trend x 95% LOD (16/193) & 5.33 copies/ml is one IU/ml is applied Limitations P0069 ViraQ HBV Trend 25 Control is not intended to be used for evaluation of the analytical or diagnostic sensitivity of NAT blood screening assays. P0069 ViraQ HBV Trend 25 Control must not be substituted for the mandatory controls or calibrators provided with IVD test kits for calculating the cut off and/or criteria for releasing test results. The Poisson distribution in samples with low HBV concentrations will imply around 92 % reactive results will be found on P0069 ViraQ HBV Trend 25 Control in NAT blood screening assays. Therefore non-reactive, or low reactive response values on the run control should not be used for a decision to reject the test run. The expected distributions of assay response values on P0069 ViraQ HBV Trend 25 that are presented in this package insert are based on evaluation studies involving a limited number of runs and reagent batches of the Ultrio and Ultrio Plus assays. It cannot be guaranteed that future reagent batches of the Ultrio Plus and Elite assay versions will generate the same reactivity. It cannot be guaranteed that the inactivated BQC standard from which P0069 ViraQ HBV Trend 25 is prepared is commutable across different NAT methods. Commutability of lyophilized or heat-inactivated virus in WHO and BQC standards with regard to reported concentrations in IU/mL and copies/ml by different quantitative HBV DNA assays has not been investigated. Therefore establishing accuracy of viral load measurements using the run control is not appropriate The manufacturers of the quantitative HBV DNA assays have prepared their internal calibrators based on different standards and this may cause systematic differences in quantitative results between methods. The accuracy of different quantitative assays in reporting in IU or copies/ml values could have been affected by the differences in calibration of the NAT systems and by heat inactivation of the BQC standard. Therefore laboratories should define their own geometric mean and 95% CI in the applied test system and interpret results according to the Westguard rules 18. P0069 ViraQ HBV Trend 25 8
9 References 1. Grabarczyk P, van Drimmelen H, Kopacz A, Gdowska J, Liszewski G, Piotrowski D, Górska J, Kuśmierczyk J, Candotti D, Lętowska M, Lelie N, Brojer E. Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors. Transfusion. 2013;53: Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, David B, and De Micco P. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009;49: Koppelman M, Assal A, Chudy M, Torres P, de Villaescusa RG, Reesink HW, Lelie PN, Cuypers HT. Multi-center performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations Transfusion 2005;45: Grabarczyk P, Koppelman M, Boland F, Sauleda S, Fabra C, Cambie G, O Riordan K, Van Drimmelen H, O Riordan J, Lelie N. Inclusion of human immunodeficiency virus type 2 (HIV-2) in a multiplex transcription mediated amplification assay does not affect detection of HBV and hepatitis B and C virus genotypes: A Multi-center performance evaluation study. Transfusion 2015 [Epub ahead of press]. 5. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R.Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group.J Clin Microbiol Jan;37(1): Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A; WHO Collaborative Study Group.An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques.vox Sang Jan;80(1): Baylis SA, Heath AB, Chudy M, Pisani G, Klotz A, Kerby S, Gerlich W.An international collaborative study to establish the 2nd World Health Organization International Standard for hepatitis B virus DNA nucleic acid amplification technology-based assays.vox Sang May;94(4): Fryer JF, Heath AB, Wilkinson DE, Minor PD and the collaborative study group. Collaborative study to evaluate the proposed 3rd WHO International Standard for hepatitis B virus (HBV) for nucleic acid amplification technology (NAT)-based assays. WHO ECBS Report 2011; WHO/BS/ Van Drimmelen A.A.J., Lelie PN. Preparation of inactivated secondary viral standards: Safety assessment of quality control samples for viral serology and NAT assays in blood screening laboratories. BQC document number CE Lelie PN, Reesink HW, Lucas CJ. Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine. J Med Virol. 1987;23: Lelie PN, Reesink HW, Niessen J, Brotman B, Prince AM. Inactivation of 10(15) chimpanzee-infectious doses of hepatitis B virus during preparation of a heatinactivated hepatitis B vaccine.j Med Virol Nov;23(3): Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha TA, Irvine BD, Tucker J, Urdea MS. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem ;226: Weusten J, Vemeulen M, Van Drimmelen H, Lelie PN. Refinement of a viral transmission risk model for blood donations in serconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011;51: P0069 ViraQ HBV Trend 25 9
10 14. Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C.Transfusion Feb;48(2): Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MY. Quantification of hepatitis B virus genomes and infectivity in human serum samples.transfusion Oct;46(10): Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion.transfusion Nov;49(11): Lelie N., Van Drimmelen H. and the International NAT Study Group. Calibration and stability of WHO and secondary viral standards. SoGAT XXIV 8-9 May 2013, Ljubljana, Slovenija 18. Centers for Disease Control (CDC). Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other blood borne pathogens in health-care settings. MMWR 1988; 37: Centers for Disease Control (CDC). Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989; 38(S-6): Westgard rules. P0069 ViraQ HBV Trend 25 10
11 P0069 ViraQ HBV Trend 25 11
12 BioQControl B.V. Visseringlaan ER Rijswijk The Netherlands Tel: +31 (0) Fax: +31 (0) Internet: KI4065 v1.0 June 2016 P0069 ViraQ HBV Trend 25 12
P0141 HBV 1000 copies/ml genotype reference panel
P0141 HBV 1000 copies/ml genotype reference panel P0141 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents
More informationP0154 ViraQ HBV Trend 50 P0154
P0154 ViraQ HBV Trend 50 P0154 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3
More informationHBV-DNA reference panels
HBV-DNA reference panels The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HBV-DNA panels
More informationP0069 ViraQ HBV Trend 25 P0069
P0069 ViraQ HBV Trend 25 P0069 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3
More informationP0063 ViraQ HCV Check 125 P0063
P0063 ViraQ HCV Check 125 P0063 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3
More informationP0064 ViraQ HIV-1 Check 125 P0064
P0064 ViraQ HIV-1 Check 125 P0064 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use...
More informationHIV-RNA reference panels
The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HIV-RNA panels for sensitivity analysis...
More informationP0067 ViraQ HCV Trend 25 P0067
P0067 ViraQ HCV Trend 25 P0067 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended use... 3
More informationP0078 SeraQ ARCHITECT P0078
P0078 SeraQ ARCHITECT P0078 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3 Key
More informationP0180 SeraQ LIAISON P0180
0 P0180 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3 Key to Symbols Used...
More informationP0063 ViraQ HCV Check 125 P0063
P0063 ViraQ HCV Check 125 P0063 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended use... 3
More informationCALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD
CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories
More informationP0064 ViraQ HIV-1 Check 125 P0064
P0064 ViraQ HIV-1 Check 125 P0064 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use...
More informationP0254 ViraQ Multi-Marker Check 125
P0254 ViraQ Multi-Marker Check 125 P0254 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance P0254 ViraQ Multi-Marker Check
More informationStability of native, lyophilized and inactivated standards
Stability of native, lyophilized and inactivated standards Harry van Drimmelen Bio Quality Control, Heiloo, Netherlands Satellite Meeting before IPFA-PEI 25 th Workshop Twenty-five Years Standardization
More informationCalibration and stability of WHO and secondary viral standards
Calibration and stability of WHO and secondary viral standards Nico Lelie, Harry van Drimmelen and the International NAT Study Group Facilities DDL Diagnostic Laboratories Outline Calibration of WHO and
More informationQuantification of HBV, HCV genotype and HIV subtype panels
Quantification of HBV, HCV genotype and HIV subtype panels Harry van Drimmelen 1,2, Wim Quint 2, Nico Lelie 3 and the international NAT study group 1. Biologicals Quality Control, 2. DDL Diagnostic Laboratory,
More informationCustomer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 sales@bioqcontrol.com
More informationCustomer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 info@bioqcontrol.com www.bioqcontrol.com
More informationAccuVert HBV Seroconversion Panel PHM941(M) ( )
PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics
More informationEvaluation of external NAT controls from two manufacturers
Evaluation of external NAT controls from two manufacturers Aneta Kopacz, Institute of Hematology and Transfusion Medicine, Warsaw, Poland NAT and External QC in Poland (2018) SCREENING Regional Blood Transfusion
More informationEvaluation of run controls for cobas 6800 MPX and HEV assay
Evaluation of run controls for cobas 6800 MPX and HEV assay Marco Koppelman Head of Nucleic Acid testing (NAT) laboratory, National Screening laboratory of Sanquin (NSS) in the Netherlands Satellite Meeting
More informationAccuSet HBV Worldwide Performance Panel
PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples
More informationUpdate from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 SOGAT XXIV Ljubljana, 8-9 May 2013 2012 ISS EQAs for NAT ISS EQA Tri-NAT (HCV,
More informationHEV Assay Development Update
HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening
More informationExperience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control
Experience with Standardisation of Blood Virology NAT Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Background of Blood Virology Standardisation In the
More informationStandardization: Calibration of. International Standards, reference preparations and working standards. Micha Nübling, PEI
Standardization: Calibration of International Standards, reference preparations and working standards Micha Nübling, PEI Paul-Ehrlich-Institut Governmental Authority for biological medicinal products Blood
More informationImpact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
More informationWHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
More informationHIV-1 Seroconversion Panel PRB973
A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians
More informationAccuVert HIV-1 Seroconversion Panel PRB974 ( )
PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers
More informationAssays to Address Emerging Threats to Blood Safety
Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of
More informationInstructions for Use (Version 3-14 th May 2003) Changes from previous version are shown in Red, deletions are shown as ^
Page 1 of 5 Page 1 of 5, 97/656 WHO 1 st International Standard for HIV-1 RNA for Nucleic Acid-Based Techniques (NAT) NIBSC code: 97/656 Instructions for Use (Version 3-14 th May 2003) Changes from previous
More informationRealLine HBV / HCV / HIV Str-Format
Instructions for use ASSAY KIT FOR THE QUALITATIVE AND DIFFERENTIAL DETECTION OF HEPATITIS B VIRUS DNA, HEPATITIS C VIRUS RNA, AND HUMAN IMMUNODEFICIENCY VIRUS TYPES 1 AND 2 RNA USING THE PCR/RT-PCR METHOD
More information1 st International Reference Panel for HIV-1 RNA Genotypes NIBSC code: 01/466
1 st International Reference Panel for HIV-1 RNA Genotypes NIBSC code: 01/466 Instructions for Use (8 th September 2004, Version 3) Changes from previous version are highlighted in red, deletions are shown
More informationKhalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia
1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples
More informationDEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE
DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut
More informationRealLine HIV quantitative Str-Format
Instructions for use DETECTION AND QUANTIFICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS RNA BY REAL TIME PCR Research Use Only (RUO) Attention! Please read the information about quantification process carefully!
More informationJohn Saldanha Regulatory Requirements: Precision and Accuracy of Quantitative NAT Tests XXII SoGAT Meeting, April, 2011
John Saldanha Regulatory Requirements: Precision and Accuracy of Quantitative NAT Tests XXII SoGAT Meeting, 14 15 April, 2011 Istituto Superiore di Sanita (ISS), Rome, Italy 2 June 2011 page 1 2011 Roche
More informationRealLine HCV Qualitative Str-Format
Instructions for use REAL TIME PCR DETECTION KIT FOR THE HEPATITIS C VIRUS RNA (HCV) Research Use Only (RUO) (Str-format) VBD0795 96 Tests valid from: October 2018 Rev05_1018_EN Page 1 of 8 Explanation
More informationHIV-1 Seroconversion Panel PRB964
A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers and clinical
More informationAccuSet Anti-HIV-1 Mixed Titer Performance Panel
PACKAGE INSERT PRB205(M3) / (0800-0379) INTENDED USE The Performance Panel PRB205(M3) / (0800-0379) is intended for use by diagnostics manufacturers and clinical laboratorians to evaluate their HIV-1 test
More informationDonor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
More informationHIV-1 Seroconversion Panel
A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The Seroconversion is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers
More informationRealLine HIV qualitative Str-Format
Instructions for Use REAL TIME PCR DETECTION KIT FOR HUMAN IMMUNODEFICIENCY VIRUS RNA Research Use Only (RUO) RealLine HIV Qualitative (Str-format) VBD0196 96 Tests valid from July 2016 Rev01072016_EN
More informationPorcine/Canine Insulin ELISA
Porcine/Canine Insulin ELISA For the quantitative determination of insulin in porcine or canine serum and plasma. Please read carefully due to Critical Changes, e.g., Calculation of Results. For Research
More informationRat Insulin ELISA. For the quantitative determination of insulin in rat serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures.
Rat Insulin ELISA For the quantitative determination of insulin in rat serum and plasma For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: Size: 80-INSRT-E01, E10 96 wells, 10
More informationAccuSet Autoimmune Performance Panel
PACKAGE INSERT 0840-0001 INTENDED USE The 0840-0001 is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot autoimmune related test
More informationGuidance for Industry
Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately
More informationBovine Insulin ELISA
Bovine Insulin ELISA For quantitative determination of insulin in bovine serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 80-INSBO-E01 Size: 96 wells Version:
More informationExternal Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience
External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience Giulio Pisani Biologicals Unit CRIVIB, ISS, Rome SOGAT XXII 14 th 15 th April 2011 - Istituto Superiore di
More informationHIV-1 AccuVert TM Seroconversion Panel
PACKAGE INSERT PRB954 (0600-0238) INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot test methods. Characterized
More informationMouse C-peptide ELISA
Mouse C-peptide ELISA For the quantitative determination of C-peptide in mouse serum. For Research Use Only. Not for use in Diagnostic Procedures. Please read carefully due to Critical Changes, e.g., Calculation
More informationProposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
More informationTechnical Bulletin No. 161
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 161 cobas 6800 HIV-1 Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationParvovirus B19 Mixed Titer Performance Panel PVP201
A SERACARE PANEL PRODUCT INTENDED USE The is a panel of naturally occurring plasma specimens. This panel is intended for use by diagnostic manufacturers and clinical laboratories to evaluate their Parvovirus
More informationAmpliX HBV Quantitative
Instructions for use REAL TIME PCR DETECTION AND QUANTITATION KIT OF HEPATITIS B VIRUS DNA Research Use Only (RUO) (Lyo-format) VBD0595 96 rcs valid from May 2013 Explanation of symbols used in labeling
More informationSee external label 2 C-8 C 96 tests CHEMILUMINESCENCE. CMV IgG. Cat # Step (20-25 C Room temp.) Volume
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationEXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2011
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2011 Collaborative Study to Evaluate the Proposed 3 rd WHO International Standard for Hepatitis B Virus (HBV) for Nucleic
More informationMouse Ultrasensitive Insulin ELISA
Mouse Ultrasensitive Insulin ELISA For the quantitative determination of insulin in mouse serum and plasma. Please read carefully due to Critical Changes, e.g., Calculation of Results. For Research Use
More informationRealLine HCV quantitative Str-Format
Instructions for use QUANTITATIVE KIT FOR REAL TIME PCR DETECTION FOR RNA OF HEPATITIS C VIRUS Attention! Please read the information about quantification process carefully! Research Use Only (RUO) (Str
More informationPROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA
PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha
More informationCYTOMEGALOVIRUS (CMV) IgM ELISA Kit Protocol
CYTOMEGALOVIRUS (CMV) IgM ELISA Kit Protocol (Cat. No.:EK-310-91) 330 Beach Road, Burlingame CA Tel: 650-558-8898 Fax: 650-558-1686 E-Mail: info@phoenixpeptide.com www.phoenixpeptide.com INTENDED USE The
More informationHIV-1 Viral Load Real Time (RG)
-1 Viral Load Real Time (RG) Real Time RT-PCR type 1 RNA quantification assay MSP Reg. pending Valdense 3616. 11700. Montevideo. Uruguay. phone (598) 2 336 83 01. Fax (598) 2 336 71 60. Info@atgen.com.uy
More informationIV2-113E Use by. Invitron Glargine ELISA Kit REF LOT IVD. Definitions. English. For in-vitro diagnostic use. Instructions for use.
Definitions Instructions for use REF Catalogue number IV2-113E Use by English Invitron Glargine ELISA Kit For in-vitro diagnostic use Σ 96 LOT IVD Lot/Batch Code Storage temperature limitations In vitro
More informationMouse C-peptide ELISA
Mouse C-peptide ELISA For the quantitative determination of C-peptide in mouse serum. For Research Use Only. Not for use in Diagnostic Procedures. Please read carefully due to Critical Changes, e.g., Preparation
More informationSputum DNA Collection, Preservation and Isolation Kit 50 Individual Devices
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Sputum DNA Collection, Preservation and Isolation Kit 50 Individual
More informationOfficial Journal of the European Communities COMMISSION
16.5.2002 EN Official Journal of the European Communities L 131/17 COMMISSION COMMISSION DECISION of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 21 September 2006 EMEA/CHMP/BWP/298390/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON
More informationRoche Molecular Biochemicals Application Note No. HP 1/1999
Roche Molecular Biochemicals Application Note No. HP 1/1999 Nucleic Acid Purification High Pure Viral Nucleic Acid Kit High Pure 16 System Viral Nucleic Acid Kit Efficiency of Hepatitis C Virus sample
More informationHepatitis C Virus (HCV) Antibody Test
Hepatitis C Virus (HCV) Antibody Test Instructions For Use Format: Cassette For: Catalog Number: VEL-001-HCV Specimen: Serum/Plasma * Please read the instructions carefully before use INTENDED USE Hepatitis
More informationRubella Latex Agglutination Test
Rubella Latex Agglutination Test Cat. No.:DLAT1088 Pkg.Size:30T Intended use The Rubella Latex Agglutination Test is a rapid latex particle agglutination test for the qualitative and semi-quantitative
More informationRat Proinsulin ELISA
Rat Proinsulin ELISA For the quantitative determination of proinsulin in rat serum For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 80-PINRT-E01 Size: 96 wells Version: June
More informationSee external label 2 C-8 C 96 tests Chemiluminescence. CMV IgM. Cat # Diluted samples, controls & calibrator 100 µl 30 minutes
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationRat C-peptide ELISA. For the quantitative determination of C-peptide in rat serum
Rat C-peptide ELISA For the quantitative determination of C-peptide in rat serum Please read carefully due to Critical Changes, e.g., see Calculation of Results. For Research Use Only. Not For Use In Diagnostic
More informationInsulin ELISA. For the quantitative determination of insulin in serum and plasma.
Insulin ELISA For the quantitative determination of insulin in serum and plasma. For In Vitro Diagnostic use within the United States of America. This product is for Research Use Only outside of the United
More informationInstructions for Use. IA-2 Antibody RIA. for the Quantitative Determination of Antibodies against Protein-Tyrosine-Phosphatase (IA2) in Serum
Instructions for Use IA-2 Antibody RIA 125I-Radioimmunoassay for the Quantitative Determination of Antibodies against Protein-Tyrosine-Phosphatase (IA2) in Serum REF RA101/50 RA104/100 50 100 2 8 C I V
More informationLeukemia BCR-ABL Fusion Gene Real Time RT-PCR Kit
Revision No.: ZJ0003 Issue Date: Aug 7 th, 2008 Leukemia BCR-ABL Fusion Gene Real Time RT-PCR Kit Cat. No.: TR-0126-02 For use with ABI Prism 7000/7300/7500/7900(96 well); Smart Cycler II; icycler iq 4/iQ
More informationAccuSet HCV Performance Panel
Signal to cutoff (s/co) DATA SHEET OVERVIEW AccuSet HCV (0810-0204) is a 25-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members
More informationInsulin ELISA. For the quantitative determination of insulin in serum and plasma
Insulin ELISA For the quantitative determination of insulin in serum and plasma For In Vitro Diagnostic use within the United States of America. This product is for Research Use Only outside of the United
More informationto be notified: all parties involved in the graduated plan procedure. Annexes
Paul-Ehrlich-Institut Postfach 63207 Langen, Germany To all marketing authorisation holders of cellular blood preparations and therapeutic single plasmas as well as authorisation holders of stem cells
More informationcobas MPX Multiplex HIV, HCV & HBV nucleic acid test for use on the cobas 6800/8800 Systems For in vitro diagnostic use cobas MPX 96 P/N:
Rx Only cobas MPX Multiplex HIV, HCV & HBV nucleic acid test for use on the cobas 6800/8800 Systems For in vitro diagnostic use cobas MPX 96 P/N: 06998909190 cobas MPX 480 P/N: 06998917190 cobas MPX Control
More informationVGKC-Autoantibody Assay RIA
Instructions for Use VGKC-Autoantibody Assay RIA 125I-Radio Immuno Assay for the Quantitative Determination of Antibodies to the Voltage-Gated Potassium Channel (VGKC) in Serum I V D REF RA115/25 25 2
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere q HIV-1/2 Detect WHO reference number: PQDx 0226-032-00 Alere q HIV-1/2 Detect with product codes 270110050, 270110010 and 270300001,
More informationInfluenza A IgG ELISA
Influenza A IgG ELISA For the qualitative determination of IgG-class antibodies against Influenza A virus in human serum or plasma (citrate, heparin). For Research Use Only. Not For Use In Diagnostic Procedures.
More informationInsulin (Porcine/Canine) ELISA
Insulin (Porcine/Canine) ELISA For the quantitative measurement of insulin in Porcine/Canine serum and plasma (EDTA) For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 80-INSPO-E01
More information1. Intended Use New Influenza A virus real time RT-PCR Panel is used for the detection of universal influenza A virus, universal swine Influenza A vir
New Influenza A Virus Real Time RT-PCR Kit User Manual LT028310RRFY - 1 - 1. Intended Use New Influenza A virus real time RT-PCR Panel is used for the detection of universal influenza A virus, universal
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationRealLine Mycoplasma genitalium Str-Format
Instructions for use ASSAY KIT FOR THE QUALITATIVE DETECTION OF MYCOPLASMA GENITALIUM DNA BY REAL-TIME PCR METHOD In vitro Diagnostics () VBD4396 96 Tests valid from December 2018 Rev06_1218_EN Page 1
More informationNational Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016
Dr. Anton van Weert National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands TransMed conference Bhopal 18 Introduction Thank you! Anton van Weert, PhD, MBA Manager
More informationNorgen s HIV proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad icycler
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com HIV Proviral DNA PCR Kit Product # 33840 Product Insert Background Information
More informationRapid-VIDITEST. Influenza A+B
Rapid-VIDITEST Influenza A+B (One step Influenza A+B blister Test for the detection of Influenza type A and type B from nasal swabs, nasal wash or nasal aspirate specimens). Instruction manual Producer:
More informationNorgen s HIV Proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad T1000 Cycler
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com HIV Proviral DNA PCR Kit Product# 33840 Product Insert Intended
More informationIVD information *Droppers for the sensitized and control cells. Not for use other than dispensing the sensitized and control cells.
In Vitro Diagnostic Reagent Instruction Manual of Diagnostic Reagent for Determination of anti-hbs Thoroughly read this instruction manual before use of this kit Background of the development and features
More informationGuidance for Industry
Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757
More informationRapid-VIDITEST Swine Flu
Rapid-VIDITEST Swine Flu One Step Influenza type A Antigen Card test. Instruction manual Producer: VIDIA spol. s r.o., Nad Safinou II 365, 252 50 Vestec, Czech Republic, Tel.: +420 261 090 565, www.vidia.cz
More informationHuman Influenza A (Swine Flu) Rapid test
Human Influenza A (Swine Flu) Rapid test Cat.No: DTSXY-Z9 Lot. No. (See product label) Size 20T Intended use The Influenza A (Swine Flu) test is a rapid chromatographic immunoassay for the qualitative
More informationHBeAg and HBeAg Ab ELISA Kit
HBeAg and HBeAg Ab ELISA Kit Catalog Number KA0290 96 assays Version: 17 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Principle of the Assay... 3
More informationPLATELIA CANDIDA Ab PLUS Negative and Positive Controls. Quality Control Human Sera
PLATELIA CANDIDA Ab PLUS Negative and Positive Controls 48 62787 Quality Control Human Sera CONTENTS 1. INTENDED USE...3 2. INDICATIONS FOR USE...3 3. REAGENTS...3 4. WARNING FOR USERS...4 5. PRECAUTIONS
More information